Recombinant Human BID Protein，His

The research on BID (BH3-interacting domain death agonist) recombinant protein stems from its critical role in apoptosis regulation and cellular stress response. BID is a pro-apoptotic member of the Bcl-2 family of proteins, which plays a pivotal role in the intrinsic pathway of apoptosis. Upon activation, BID is cleaved to form a truncated form known as tBID, which translocates to the mitochondria and facilitates the release of cytochrome c, ultimately leading to cell death. Understanding the mechanisms by which BID and its derivatives operate is essential for elucidating how cells balance survival and death in physiological and pathological conditions, including cancer, neurodegeneration, and ischemic injury. Researchers have increasingly focused on the recombinant expression of BID and tBID to study their structure-function relationships, binding affinities with other apoptotic regulators, and potential therapeutic applications. By generating and characterizing BID recombinant proteins, scientists aim to develop novel strategies for manipulating apoptosis in cancer therapies, promoting cell survival in neurodegenerative diseases, and enhancing protective mechanisms against cellular damage. The intricate interplay between BID and other apoptotic mediators highlights its significance as a target in drug design and provides valuable insights into the development of more effective treatment regimens aimed at diseases characterized by dysregulated apoptosis.